Business Context and Reporting Period
Company: BioCardia, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 24, 2025
Reporting Period: Event-based report for July 24, 2025.
Business Overview: BioCardia is a biotechnology company focused on developing autologous cell therapies for heart failure. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol BCDA.
Key Financial Metrics
This Form 8-K is an event-driven filing and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The filing reports a significant regulatory milestone rather than a financial change. On July 24, 2025, the Company submitted its CardiAMP autologous cell therapy investigational heart failure treatment for clinical consultation with Japan's Pharmaceuticals and Medical Devices Agency (PMDA). This action represents a strategic step toward potential regulatory approval in Japan, identified as a key market for advanced heart failure therapies.
Guidance, Outlook, and Risks
Outlook: Management views the submission to the PMDA as a significant step toward potential regulatory approval in Japan.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the inherent uncertainties of the regulatory approval process. The press release attached as Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting its legal liability status.
Key Facts for Investor Verification
- Verify the status and timeline of the clinical consultation with Japan's PMDA for the CardiAMP therapy.
- Confirm the specific requirements and next steps outlined by the PMDA following the submission.
- Review the attached press release (Exhibit 99.1) for detailed commentary on the Japanese market strategy.
- Check subsequent filings for any updates on the regulatory consultation outcome or changes to the development timeline.